Jefferies analyst Andrew Tsai notes that Beckley Psytech shared positive Phase 2a data on BPL-003 in combination with SSRI antidepressants for treatment-resistant depression that the firm calls “encouraging.” The drug’s profile seems to be consistent across multiple studies, incrementally de-risking the key Phase 2b TRD study in mid-2025, the analyst tells investors. Although the BPL-003 program is controlled by Beckley Psytech, Atai Life Sciences (ATAI) currently holds about a 34% stake in Beckley that can be increased to 45%-plus for about $60M, adds the analyst, who has a Buy rating and $5 price target on Atai shares.

Confident Investing Starts Here:

Easily unpack a company's performance  with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox  with TipRanks' Smart Value Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on ATAI:

Disclaimer & DisclosureReport an Issue

Home Depot backs outlook as U.S. sales ticked up: Morning Buzz Atai Life Sciences announces data from Part 2 of Phase 2a study of BPL-003 ATAI Life Sciences: Positioned for Leadership in Scalable Psychedelic Psychiatry with Strong Financial Foundation and Promising Clinical Milestones ATAI Life Sciences: Strong Buy Rating Backed by Promising Trials and Robust Financial Health ATAI Life Sciences: Buy Rating Backed by Promising Pipeline and Strong Cash Position Amid Upcoming Catalysts

View Comments